NCT07747350

Brief Summary

All patients will be treated using the fixed appliance on the upper and lower arches. 0.014" Niti archwire is used to ensure all patients will receive the same force. All participants will receive a pain diary. In the pain diary, they are required to complete a KAP questionnaire regarding pain before the procedure. They are also required to record the pain VAS score at different times (before procedure, 6 hours, 12 hours, 24 hours, 3 days, 5 days and 7 days after procedure). For PCM 650mg group, 1 tablet will be given 1 hour before the procedure and every 6 hours for 24 hours (5 doses in total) (Nik et al., 2016) as pain begins two hours after activation, peak at 24 hours and reduces after two days (Nik et al 2016). Paracetamol if taken more than 4g per day may cause serious liver damage. United State of Food and Drugs Administration recently suggested a maximum daily dose of 3g to reduce risk of overdosing (Kim et al, 2020, FDA, 2011). Based on literature, 1000mg PCM is more efficient as postoperative analgesics 1000mg vs 650mg vs placebo (SPRID6 score of 529.4 vs 427.3 vs 60.0) (Qi et al, 2012). However, this study reported a single dose application (up to 6 hours). In view of continuous pain sensation experience by orthodontic patients (peak at 24 hours), we concluded that 650mg 6 hourly is more appropriate to control pain experienced by participants. For LLLT group: ezlase diode laser beam (Biolase, USA) for soft tissue operated at 940nm wavelength will be applied using a quadrant-sized probe that covers region form central incisor to first molar at the level of cervical third of the root, perpendicular and in light, direct contact with the buccal and palatal mucosa for the upper arch and buccal and lingual mucosa for the lower arch from UR6-UL6 and LR6- LL6 for 30 seconds each site (AlSayed Hasan et al., 2018; Qamruddin et al., 2021). Patients will be monitored up to 1 hour after the LLLT application for any adverse reactions. All procedures will be conducted in the morning session from 9am- 11am. Due to variability of pain experienced throughout the day (Aviram et al, 2015), patients are advised to record pain in the morning to reduce the variability in VAS score. All the procedures and baseline score will also be conducted and recorded in the morning. During the follow-up appointment (1 month after bond-up) Patients are required to re-answer the KAP questionnaire (post bond-up) in the pain diary. Pain diary will be collected for data analysis.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
30

participants targeted

Target at below P25 for not_applicable

Timeline
7mo left

Started Feb 2026

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress49%
Feb 2026Feb 2027

Study Start

First participant enrolled

February 1, 2026

Completed
Same day until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2026

Completed
6 months until next milestone

First Submitted

Initial submission to the registry

July 30, 2026

Completed
6 days until next milestone

First Posted

Study publicly available on registry

August 5, 2026

Completed
7 months until next milestone

Study Completion

Last participant's last visit for all outcomes

February 20, 2027

Expected
Last Updated

August 5, 2026

Status Verified

July 1, 2026

Enrollment Period

Same day

First QC Date

July 30, 2026

Last Update Submit

July 30, 2026

Conditions

Outcome Measures

Primary Outcomes (2)

  • Pain Intensity Score

    Pain evaluated using the Visual Analog Scale (VAS) ranging from 0 (no pain) to 10 (worst imaginable pain)

    Assessed at 6, 12, 24, 48, and 72 hours following archwire placement

  • Orthodontic Pain Score

    Pain evaluated using the Visual Analog Scale (VAS) ranging from 0 (no pain) to 10 (worst imaginable pain)

    Assessed at 6, 12, 24, 48, and 72 hours following archwire placement

Study Arms (2)

Low Level Laser Therapy Group

EXPERIMENTAL

Participants in this group will receive Low-Level Laser Therapy (LLLT) following orthodontic archwire placement or adjustment to evaluate its effectiveness in reducing orthodontic pain

Device: Low-Level Laser Therapy (LLLT)

Conventional Analgesics Group

ACTIVE COMPARATOR

Participants in this group will receive conventional oral analgesics (e.g., Paracetamol) for pain relief following orthodontic activation

Drug: Conventional Analgesic (Paracetamol)

Interventions

Low-level laser therapy (LLLT) will be applied to the target teeth and buccal/lingual gingival tissues immediately after orthodontic archwire placement or adjustment to evaluate its effectiveness in reducing orthodontic pain

Also known as: Low-Level Laser Application
Low Level Laser Therapy Group

Oral administration of conventional analgesics (e.g., Paracetamol) as needed for orthodontic pain relief after archwire placement

Also known as: analgesic
Conventional Analgesics Group

Eligibility Criteria

Age18 Years - 33 Years
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • Age 18- 33 years old
  • Malay
  • Female
  • Fit and Healthy
  • New patients who have not received any orthodontic treatment

You may not qualify if:

  • Patient with a history of pain and medical problem
  • Patient who had taken medication for the past 2 weeks before orthodontic treatment
  • Patient with craniofacial deformities

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

School of Dental Sciences Universiti Sains Malaysia

Kota Bharu, KOTA BHARU, Malaysia

RECRUITING

MeSH Terms

Interventions

Low-Level Light TherapyAcetaminophenAnalgesics

Intervention Hierarchy (Ancestors)

Laser TherapyTherapeuticsPhototherapyAcetanilidesAnilidesAmidesOrganic ChemicalsAniline CompoundsAminesSensory System AgentsPeripheral Nervous System AgentsPhysiological Effects of DrugsPharmacologic ActionsChemical Actions and UsesCentral Nervous System AgentsTherapeutic Uses

Central Study Contacts

ROA RAAD FAFHEL, MSc STUDENT

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
dentist

Study Record Dates

First Submitted

July 30, 2026

First Posted

August 5, 2026

Study Start

February 1, 2026

Primary Completion

February 1, 2026

Study Completion (Estimated)

February 20, 2027

Last Updated

August 5, 2026

Record last verified: 2026-07

Locations